<DOC>
	<DOCNO>NCT00798148</DOCNO>
	<brief_summary>This trial study well iodine I 131 metaiodobenzylguanidine together combination chemotherapy work treat patient undergo autologous peripheral stem cell high risk relapse neuroblastoma .</brief_summary>
	<brief_title>131I-MIBG With Myeloablative Chemotherapy Autologous Stem Cell Transplantation Treatment High-risk Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Histologically confirm Neuroblastoma and/or demonstration tumor cell bone marrow elevate urinary catecholamine metabolite High risk accord COG ( Children Oncology Group ) OR Relapse OR Refractory As least one I131MIBG avid target lesion determine diagnostic MIBG scan Glomerular filtration rate creatinine clearance &gt; 60 ml/min No tumor cell Bone Marrow routine morphology aspiration biopsy peripheral stem cell collection No active infection Impaired renal function No avid I131MIBG lesion Active infection</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>MIBG</keyword>
	<keyword>Autologous Peripheral Stem Cell Transplantation</keyword>
</DOC>